NASDAQ$ACLX
Arcellx Inc · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Reported financial results for the third quarter of 2023 and provided recent business highlights.
Arcellx reported collaboration revenue of $15.0 million for Q3 2023, driven by the Kite Pharma agreement. The company's cash, cash equivalents, and marketable securities totaled $482.7 million as of September 30, 2023, expected to fund operations into 2026. Net loss for the quarter was $39.3 million.
- Announced oral presentation at ASH in December, highlighting CART-ddBCMA trial data with median follow-up of 22 months.
- CART-ddBCMA continues to be well-tolerated with no observed delayed neurotoxicities or parkinsonian symptoms.
- Resumed enrollment in iMMagine-1 study, advancing the program towards commercial availability.
- New clinical data from CART-ddBCMA Phase 1 trial will be presented at the ASH Annual Meeting.
Headline financials
Revenue & EPS history
Arcellx · Revenue · Quarterly
$15M
Forward guidance
Arcellx anticipates that its cash, cash equivalents, and marketable securities will fund its operations into 2026.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2023
+2.2%
Avg return
Earnings day
+0.1%
Avg return
5 days after
+24.9%
Avg return
30 days after
58%
11 / 19 earnings
Positive
+16.0%
Q2 2024
Best reaction
-4.8%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -0.2% | -0.1% | +0.2% | |
| Q3 2025 | -1.9% | +2.2% | -21.1% | |
| Q2 2025 | -0.9% | -0.2% | +2.1% | |
| Q1 2025 | -0.2% | +10.9% | +9.0% | |
| Q4 2024 | +2.0% | +1.2% | -19.9% | |
| Q3 2024 | +10.8% | +8.1% | -9.1% | |
| Q2 2024 | +16.0% | +19.1% | +40.0% | |
| Q1 2024 | -4.8% | -3.1% | -2.8% | |
| Q4 2023 | -2.7% | +0.4% | +2.9% | |
| Q3 2023 | +4.3% | +21.3% | +11.0% | |
| Q2 2023 | +6.7% | +3.3% | -0.7% | |
| Q1 2023 | +2.8% | -4.5% | -3.7% | |
| Q4 2022 | +0.9% | -2.9% | +41.1% | |
| Q3 2022 | -2.8% | -4.9% | +47.5% | |
| Q3 2021 | -2.8% | -4.9% | +47.5% | |
| Q2 2022 | +8.4% | -4.1% | +10.5% | |
| Q1 2022 | +0.2% | -15.5% | +174.8% | |
| Q1 2021 | +0.2% | -15.5% | +174.8% | |
| Q4 2021 | +5.9% | -8.7% | -30.2% | |
| Q4 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro